Details of Disease

General Information of Disease (ID: DISJW62S)

• Disease Name: Heart failure
• Synonyms: heart failure; cardiac failure; cardiac insufficiency; failure, heart; insufficiency, Cardiac
• Disease Class: BD10-BD1Z: Heart failure
• Definition: Inability of the heart to pump blood at an adequate rate to meet tissue metabolic requirements. Clinical symptoms of heart failure include: unusual dyspnea on light exertion, recurrent dyspnea occurring in the supine position, fluid retention or rales, jugular venous distension, pulmonary edema on physical exam, or pulmonary edema on chest x-ray presumed to be cardiac dysfunction.
• Disease Hierarchy:
  DISVO1I5: Cardiac disease
  DISJW62S: Heart failure
• ICD Code: ICD-11: ICD-11: BD10-BD13
• Disease Identifiers:
  MONDO ID: MONDO_0005252
  MESH ID: D006333
  UMLS CUI: C0018801
  MedGen ID: 6749
  SNOMED CT ID: 84114007

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 12 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Acocantherin	DM7JT24	Approved	Small molecular drug	[1]
Deslanoside	DMB3ZSK	Approved	Small molecular drug	[2]
Digitoxin	DMWVIGP	Approved	Small molecular drug	[3]
Digoxin	DMQCTIH	Approved	Small molecular drug	[4]
Dobutamine	DMD1B8Z	Approved	Small molecular drug	[5]
Eplerenone	DMF0NQR	Approved	Small molecular drug	[6]
LCZ696	DMLFX7K	Approved	Small molecular drug	[7]
Levosimendan	DMKBOS2	Approved	Small molecular drug	[8]
Olprinone	DMWBQKU	Approved	Small molecular drug	[9]
Sotagliflozin	DMMLXA9	Approved	Small molecular drug	[10]
Tolvaptan	DMIWFRL	Approved	Small molecular drug	[11]
Vericiguat	DM7MDBE	Approved	Small molecular drug	[12]

This Disease is Treated as An Indication in 62 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AR-06	DMMA487	Phase 3	NA	[13]
Bendavia	DMK43ON	Phase 3	NA	[13]
CardiAMP	DMTI61M	Phase 3	Cell therapy	[14]
ELAD	DMVFDGL	Phase 3	NA	[15]
Entresto	DMTWLXY	Phase 3	NA	[13]
Ixmyelocel-T	DMW7UL0	Phase 3	NA	[13]
MPC-150-IM	DMLZ7KQ	Phase 3	NA	[13]
MyoCell SDF-1	DMS9GE1	Phase 3	NA	[16]
Neucardin	DME617W	Phase 3	NA	[17]
Omecamtiv mecarbil	DM624TW	Phase 3	Small molecular drug	[13]
RBT-101	DMDZW8K	Phase 3	NA	[18]
Rolofylline	DMSZPR3	Phase 3	Small molecular drug	[19]
Ularitide	DM90AG2	Phase 3	Small molecular drug	[20]
Ziltivekimab	DME841B	Phase 3	NA	[21]
Oxypurinol	DMURH4X	Phase 2/3	Small molecular drug	[22]
18F-LMI-1195	DM8JVIB	Phase 2	NA	[23]
AIR-001	DM5ON6G	Phase 2	NA	[13]
AMR-001	DMGE8FK	Phase 2	NA	[24]
AZD3427	DM5ABFB	Phase 2	NA	[25]
AZD9977	DM3LFDH	Phase 2	Small molecule	[26]
BAY 1067197	DM4JGNH	Phase 2	NA	[27]
BAY 11-42524	DM8SNEM	Phase 2	NA	[28]
BEMORADAN	DMUL6GY	Phase 2	Small molecular drug	[29]
BR-4628	DMNFKVW	Phase 2	NA	[30]
Cenderitide	DMCT8EY	Phase 2	NA	[31]
COR-1	DMER82Z	Phase 2	NA	[32]
CRD-740	DMRTX0K	Phase 2	NA	[33]
ERC-124	DMMXJ33	Phase 2	NA	[34]
Etamicastat	DM71BZV	Phase 2	Small molecular drug	[35]
GSK2798745	DM7V96W	Phase 2	NA	[13]
IW-1973	DMK2T7J	Phase 2	NA	[13]
JNJ-39588146	DMN6CQ2	Phase 2	NA	[36]
LIK-066	DM32NWD	Phase 2	NA	[13]
LMI1195	DMUS20Z	Phase 2	NA	[23]
Mydicar	DM25VY8	Phase 2	NA	[37]
Org-30029	DMDZ4R2	Phase 2	Small molecular drug	[38]
PB1046	DM8MJ3F	Phase 2	Recombinant protein	[13]
PL-3394	DMC1SOS	Phase 2	NA	[13]
Ponsegromab	DM5HO2X	Phase 2	Monoclonal antibody	[39]
SDF-1	DM80HOV	Phase 2	NA	[40]
SER-100	DMDW5ZC	Phase 2	NA	[41]
SERCA 2a gene therapy	DMAG6LB	Phase 2	NA	[13]
SLV320	DM867BJ	Phase 2	Small molecular drug	[42]
SPD-556	DM9OPK3	Phase 2	Small molecular drug	[43]
TRV027	DMVX6H0	Phase 2	NA	[44]
Vericigiuat	DM104SP	Phase 2	NA	[45]
AdipoCell	DM347BM	Phase 1/2	NA	[46]
AMG 986	DMZQ2DK	Phase 1	NA	[13]
AZD4831	DMRP3N8	Phase 1	NA	[13]
BAY 86-8050	DM31RQS	Phase 1	NA	[47]
BR6819	DMOQ2GB	Phase 1	NA	[13]
CardiALLO	DM7ZHF6	Phase 1	NA	[13]
Drug 2881078	DMWXQC9	Phase 1	NA	[48]
GGF-2	DMDMPKC	Phase 1	NA	[49]
GSK3884464	DMU6KXH	Phase 1	NA	[50]
hESC-derived CD15+ISL-1+cardiac progenitors	DMBAIJS	Phase 1	Human embryonic stem (hES) cell-derived therapeutics	[51]
INXN 4001	DM6U06L	Phase 1	Gene therapy	[52]
MRG-110	DMUVGMS	Phase 1	Oligonucleotide	[53]
TD-0714	DMO8L6T	Phase 1	NA	[13]
TD-1439	DMGZ54W	Phase 1	NA	[13]
TT-00920	DMP6G0P	Phase 1	Small molecule	[54]
SZ004	DMLOPDK	Clinical trial	NA	[55]

This Disease is Treated as An Indication in 15 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
NOLOMIROLE HYDROCHLORIDE	DMJL5TR	Discontinued in Phase 3	Small molecular drug	[56]
Ilepatril	DMTR50E	Discontinued in Phase 2/3	NA	[57]
ARM036	DMNGQM0	Discontinued in Phase 2	Small molecular drug	[58]
AVE-8134	DMCX6MD	Discontinued in Phase 2	NA	[59]
BAY 60-4552	DMAQT8D	Discontinued in Phase 2	Small molecular drug	[60]
NSP-805	DMH2QBM	Discontinued in Phase 2	Small molecular drug	[61]
Org-9731	DMZEV63	Discontinued in Phase 2	NA	[62]
Otenzepad	DMRXHAC	Discontinued in Phase 2	Small molecular drug	[63]
Candoxatrilat	DMQIWZL	Discontinued in Phase 1	Small molecular drug	[64]
CDP-1050	DM5BG4P	Discontinued in Phase 1	NA	[65]
GSK2849466	DMM7Q3L	Discontinued in Phase 1	NA	[66]
Etomoxir	DM3BHN1	Terminated	Small molecular drug	[69]
LAS-31180	DMW2K1L	Terminated	Small molecular drug	[70]
UD-CG-212	DM9FT5E	Terminated	NA	[71]
VUF-8929	DM0CWJZ	Terminated	Small molecular drug	[72]

This Disease is Treated as An Indication in 2 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BMS-986046	DMH7QIF	Preclinical	NA	[67]
Rycals	DMXM2BZ	Preclinical	NA	[68]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CAMI-103	DM4P8EX	Investigative	NA	[73]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4826).
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6806).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6782).
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4726).
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 535).
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2876).
• [7] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [8] ClinicalTrials.gov (NCT04705337) Levosimendan In Ambulatory Heart Failure Patients (LEIA-HF). U.S. National Institutes of Health.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [10] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216203.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2226).
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] ClinicalTrials.gov (NCT02438306) CardiAMP Heart Failure Trial. U.S. National Institutes of Health.
• [15] Clinical pipeline report, company report or official report of Vital therapies.
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021307)
• [17] ClinicalTrials.gov (NCT01214096) Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure. U.S. National Institutes of Health.
• [18] Constrained peptides' time to shine. Nat Rev Drug Discov. 2018 Jul 30;17(8):531-533.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5604).
• [20] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8446).
• [21] ClinicalTrials.gov (NCT05636176) HERMES: Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation. U.S.National Institutes of Health.
• [22] ClinicalTrials.gov (NCT00063687) Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure. U.S. National Institutes of Health.
• [23] ClinicalTrials.gov (NCT01085175) Trial to Determine Imaging Parameters of LMI1195 in Heart Failure Patients at Low and High Risk of Defibrillator Firing. U.S. National Institutes of Health.
• [24] ClinicalTrials.gov (NCT01495364) NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction. U.S. National Institutes of Health.
• [25] ClinicalTrials.gov (NCT05737940) A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2). U.S.National Institutes of Health.
• [26] ClinicalTrials.gov (NCT04595370) A Phase 2b, Randomised, Double-Blind, Active Controlled, Multi Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients With Heart Failure and Chronic Kidney Disease. U.S.National Institutes of Health.
• [27] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035637)
• [28] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040276)
• [29] Evaluation of the excretion, and metabolism of the cardiotonic agent bemoradan in male rats and female beagle dogs. Eur J Drug Metab Pharmacokinet. 2001 Oct-Dec;26(4):263-71.
• [30] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027127)
• [31] 2011 Pipeline of Nile Therapeutics.
• [32] Administration of the cyclic peptide COR-1 in humans (phase I study): ex vivo measurements of anti-beta1-adrenergic receptor antibody neutralization and of immune parameters. Eur J Heart Fail. 2012 Nov;14(11):1230-9.
• [33] ClinicalTrials.gov (NCT05409183) A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Effectiveness of CRD-740 in Subjects With Chronic Heart Failure (CARDINAL-HF). U.S.National Institutes of Health.
• [34] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035572)
• [35] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034724)
• [36] ClinicalTrials.gov (NCT01120210) A Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of an Intravenous Solution of JNJ-39588146 or Placebo in Patients With Heart Failure. U.S. National Institutes of Health.
• [37] ClinicalTrials.gov (NCT00534703) Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients With Chronic Heart Failure and a Left Ventricular Assist Device. U.S. National Institutes of Health.
• [38] Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ Res. 1993 Mar;72(3):597-606.
• [39] ClinicalTrials.gov (NCT05492500) A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 4-ARM STUDY TO INVESTIGATE SYMPTOMS, FUNCTION, HEALTH-RELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE. U.S.National Institutes of Health.
• [40] ClinicalTrials.gov (NCT01643590) Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure.. U.S. National Institutes of Health.
• [41] ClinicalTrials.gov (NCT00283361) ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure. U.S. National Institutes of Health.
• [42] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3281).
• [43] ClinicalTrials.gov (NCT01179607) Study of Efficacy of a Vasopressin 2 Receptor Antagonist M0002 for Treatment of Ascites in Cirrhotic Subjects With Hypo- or Normonatraemia. U.S. National Institutes of Health.
• [44] ClinicalTrials.gov (NCT01966601) A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure. U.S. National Institutes of Health.
• [45] Clinical pipeline report, company report or official report of Bayer HealthCare Pharmaceuticals.
• [46] Clinical pipeline report, company report or official report of Bioheart.
• [47] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035638)
• [48] ClinicalTrials.gov (NCT02567773) Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078.
• [49] ClinicalTrials.gov (NCT01258387) Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure. U.S. National Institutes of Health.
• [50] ClinicalTrials.gov (NCT05044325) A Two-Part First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Oral Doses of GSK3884464 in a Randomized, Double Blind, Placebo-Controlled, Dose Escalation Study in Healthy Participants. U.S.National Institutes of Health.
• [51] ClinicalTrials.gov (NCT02057900) Transplantation of Human Embryonic Stem Cell-derived Progenitors in Severe Heart Failure
• [52] ClinicalTrials.gov (NCT03409627) Novel INXN-4001 Triple Effector Plasmid in Heart Failure. U.S. National Institutes of Health.
• [53] ClinicalTrials.gov (NCT03603431) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRG-110 Following Intradermal Injection in Healthy Volunteers. U.S. National Institutes of Health.
• [54] Clinical pipeline report, company report or official report of TransThera Biosciences
• [55] Clinical pipeline report, company report or official report of Sarfez Pharmaceuticals
• [56] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003364)
• [57] Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension. Curr Opin Investig Drugs. 2008 Mar;9(3):301-9.
• [58] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034371)
• [59] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021122)
• [60] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028283)
• [61] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002110)
• [62] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005468)
• [63] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 309).
• [64] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6491).
• [65] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029695)
• [66] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036899)
• [67] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035005)
• [68] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030217)
• [69] Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res. 1988 Dec;63(6):1036-43.
• [70] Pharmacological profile of LAS 31180, a new inotropic/vasodilator quinolone derivative. Arzneimittelforschung. 2000 Nov;50(11):980-6.
• [71] Electrophysiological actions of the pimobendan metabolite, UD-CG 212 Cl, in guinea pig myocardium. J Pharmacol Exp Ther. 1992 Jan;260(1):58-63.
• [72] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009533)
• [73] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [74] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015